[关键词]
[摘要]
目的 探讨养血清脑颗粒联合艾地苯醌治疗血管性痴呆的临床疗效。方法 选取2018年1月-2019年12月在河南省荣军医院治疗的血管性痴呆患者90例,随机分为对照组(45例)和治疗组(45例)。对照组饭后口服艾地苯醌片,1片/次,3次/d。治疗组在对照组的基础上口服养血清脑颗粒,1袋/次,3次/d。两组患者连续治疗60 d。观察两组患者临床疗效,同时比较治疗前后两组患者简易智能精神状态量表(MMSE)和日常生活能力量表(ADL)评分,及血清丙二醛(MDA)、超氧化物歧化酶(SOD)和脑源性神经营养因子(BDNF)水平。结果 治疗后,对照组和治疗组临床有效率分别为77.78%和93.33%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者MMSE、ADL评分显著上升(P<0.05),且治疗组明显高于对照组(P<0.05)。治疗后,两组患者血清MDA水平显著下降(P<0.05),SOD、BDNF水平显著上升(P<0.05),且治疗组改善情况明显好于对照组(P<0.05)。结论 养血清脑颗粒联合艾地苯醌治疗血管性痴呆疗效确切,促进患者认知功能和生活能力改善,保护神经元,减轻氧化应激反应。
[Key word]
[Abstract]
Objective To explore the clinical effect of Yangxue Qingnao Granules combined with idebenone in treatment of vascular dementia. Methods Patients (90 cases) with vascular dementia in Henan Rongjun Hospital from January 2018 to December 2019 were randomly divided into control (45 cases) and treatment (45 cases) groups. Patients in the control group were po administered with Idebenone Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Yangxue Qingnao Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 60 d. After treatment, the clinical efficacy was evaluated, and the MMSE and ADL scores, the serum levels of MDA, SOD and BDNF in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 77.78% and 93.33% respectively, and there were differences between two groups (P<0.05). After treatment, the MMSE and ADL scores in two groups were significantly increased (P<0.05), and which in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of MDA in two groups were significantly decreased (P<0.05), but the SOD and BDNF levels in two groups were significantly increased (P<0.05), and these indicators in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Yangxue Qingnao Granules combined with idebenone has a significant clinical effect on vascular dementia, can improve the cognitive function and the ability of daily life, protect neurons, and reduce oxidative stress.
[中图分类号]
R971
[基金项目]